TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: In the phase 2 NCT01421667 study, patients with R/R CD30‐positive peripheral T‐cell lymphoma (PTCL) receiving BV achieved an ORR of 41%; for patients with angioimmunoblastic T‐cell lymphoma, the ORR was 54%, and the median PFS was 6.7 months.78